Teva Branded Pharmaceutical Products R&D LLC
Clinical trials sponsored by Teva Branded Pharmaceutical Products R&D LLC, explained in plain language.
Research and development subsidiary of Teva, focusing on branded pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot aims to shield celiac patients from gluten damage Results expected Sep 2026 (estimated)
- New combo inhaler aims to ease asthma symptoms Results expected Sep 2026 (estimated)
- New combo inhaler aims to cut severe asthma Flare-Ups Results expected Oct 2026 (estimated)
- First human tests begin for experimental drug TEV-56286 Results expected Jan 2027 (estimated)
-
New drug combo for blood cancer tested in early trial
Disease control Stopped earlyThis early-phase study tested a new drug called modakafusp alfa combined with daratumumab in 15 people with multiple myeloma that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose. The trial was terminated early, so full…
Phase 1/2 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental cancer drug combo tested in early trial
Disease control Stopped earlyThis early-phase trial tested the safety and dosing of a new drug called modakafusp alfa, given alone or with pembrolizumab, in adults with advanced solid tumors or melanoma. The study aimed to find the highest safe dose and check for side effects. It was terminated early, so res…
Phase 1/2 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental myeloma drug shows promise but trial halted early
Disease control Stopped earlyThis study tested a new drug called modakafusp alfa in 272 people with multiple myeloma that had returned or stopped responding to other treatments. The goal was to check safety and see if the drug could shrink tumors. The trial was terminated early, but researchers collected dat…
Phase 1/2 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental myeloma combo trial halted early
Disease control Stopped earlyThis early-stage trial tested a new drug called modakafusp alfa (TAK-573) combined with standard myeloma treatments in 15 adults with multiple myeloma. The main goal was to check safety and find the best dose. The study was terminated early, so we have limited information on how …
Phase 1 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC